Lakshmi P. Kotra
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lakshmi P. Kotra has a total of 273 co-authors. Here are the top co-authors by number of shared publications:
Lianhu Wei
Center for Molecular Design and Preformulations, and Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario M5G 1L7, Canada
25 shared publicationsAngelica M. Bello
Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto , Toronto, Ontario M5S 3M2, Canada
19 shared publications- Emil F. Pai
Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada
16 shared publications Ewa Poduch
Center for Molecular Design and Preformulations, Toronto General Research Institute, University Health Network, Toronto, Ontario M5G 1L7, Canada
12 shared publicationsEwa Wasilewski
Krembil Research Institute, University Health Network, 5-356 PMCRT/MaRS, 101 College Street, Toronto, Ontario M5G 2L7, Canada
9 shared publicationsShahriar Mobashery
9 shared publications
Latest Publications
- Open Access
- 25 July 2025
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 10 (30) , 33401-33414
Synthesis and Biological Evaluation of Small Molecule Inhibitors of Immune Cytopenias
Immune cytopenias are a group of autoimmune disorders where patients develop autoantibodies against certain types of blood cells such as red blood cells (RBCs) or thrombocytes. We investigated small molecules as potential inhibitors of phagocytosis of blood cells that are prevalent in immune thrombocytopenia (ITP) and warm autoantibody immune hemolytic anemia (wAIHA). Upon screening a chemical library of over 13,000 compounds in silico, followed by evaluating 80 compounds in vitro as inhibitors of phagocytosis of opsonized RBCs by monocytes, we identified four hit molecules. These compounds contain a pyrazole moiety as a key structural feature. Here, we reveal the independent synthesis and re-evaluation of these hits, as well as revalidate the biological activities and the synthesis of their analogs to understand the structure–activity relationships. Two of the resynthesized compounds showed up to a 9-fold difference in their inhibitory activities between the commercial and synthesized batches, and the analogs exhibited either equal or weaker potency than the parent compounds targeting phagocytosis of RBCs. The role of regioisomers and the importance of an ester moiety are revealed as important structural features through these analogs. The pharmacokinetics of the promising compound 33 suggested that this compound shows significant efficacy in restoring platelet counts in the mouse model of ITP, despite the rapid hydrolysis of its methyl ester moiety.
- 25 July 2025
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 10 (30) , 33401-33414
Open AccessSynthesis and Biological Evaluation of Small Molecule Inhibitors of Immune Cytopenias
Immune cytopenias are a group of autoimmune disorders where patients develop autoantibodies against certain types of blood cells such as red blood cells (RBCs) or thrombocytes. We investigated small molecules as potential inhibitors of phagocytosis of blood cells that are prevalent in immune thrombocytopenia (ITP) and warm autoantibody immune hemolytic anemia (wAIHA). Upon screening a chemical library of over 13,000 compounds in silico, followed by evaluating 80 compounds in vitro as inhibitors of phagocytosis of opsonized RBCs by monocytes, we identified four hit molecules. These compounds contain a pyrazole moiety as a key structural feature. Here, we reveal the independent synthesis and re-evaluation of these hits, as well as revalidate the biological activities and the synthesis of their analogs to understand the structure–activity relationships. Two of the resynthesized compounds showed up to a 9-fold difference in their inhibitory activities between the commercial and synthesized batches, and the analogs exhibited either equal or weaker potency than the parent compounds targeting phagocytosis of RBCs. The role of regioisomers and the importance of an ester moiety are revealed as important structural features through these analogs. The pharmacokinetics of the promising compound 33 suggested that this compound shows significant efficacy in restoring platelet counts in the mouse model of ITP, despite the rapid hydrolysis of its methyl ester moiety.
- Open Access
- 23 November 2024
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 117, 118019
Stereoisomers of cannabidiols and their pharmacological activities – A potentially novel direction for cannabinoids
- 23 November 2024
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 117, 118019
Open AccessStereoisomers of cannabidiols and their pharmacological activities – A potentially novel direction for cannabinoids
- Open Access
- 7 November 2024
- Published by Wiley in Transfusion
- Vol. 64 (12) , 2233-2240
A novel small molecule phagocytosis inhibitor, KB‐208, ameliorates ITP in mouse models with similar efficacy as IVIG
Background: The characteristic feature of immune cytopenias involves the process of extravascular phagocytosis, wherein macrophages in the spleen and/or liver engage in the destruction of blood cells that have been opsonized by auto‐ or alloantibodies. Therefore, new treatments that prevent phagocytosis will be advantageous, especially for short‐term usage along with alternative options.Study Design and Methods: KB‐208, a small molecule drug, previously shown to be efficacious for the in vitro inhibition of phagocytosis was synthesized. A passive antibody mouse model of immune thrombocytopenia (ITP) was used. Three different mouse strains (BALB/c, C57BL/6, CD1) were used to determine the efficacy of KB‐208 compared with IVIG to ameliorate the ITP. Toxicity was investigated after 60‐day chronic administration of KB‐208 by a biochemistry panel, gross necroscopy and histopathology.Results: KB‐208 showed similar efficacy to ameliorate the thrombocytopenia compared with IVIG in all three mouse strains. This small molecule drug was effective at 1 mg/kg in ameliorating ITP, in comparison with IVIG at 1000–2500 mg/kg. KB‐208 did not affect other blood parameters or elevate serum biochemistry markers of toxicity nor were any abnormal histopathological findings found.Conclusion: KB‐208 is similar to IVIG for the amelioration of ITP in multiple mouse strains. Chronic administration of KB‐208 for 60 days did not demonstrate in vivo toxicity. These findings indicate that KB‐208 is efficacious, without significant in vivo toxicities in mice, and is a potential small molecule candidate for further evaluation to be used in the treatment of ITP and possibly all immune cytopenias where phagocytosis is responsible for the pathophysiology.
- 7 November 2024
- Published by Wiley in Transfusion
- Vol. 64 (12) , 2233-2240
Open AccessA novel small molecule phagocytosis inhibitor, KB‐208, ameliorates ITP in mouse models with similar efficacy as IVIG
Background: The characteristic feature of immune cytopenias involves the process of extravascular phagocytosis, wherein macrophages in the spleen and/or liver engage in the destruction of blood cells that have been opsonized by auto‐ or alloantibodies. Therefore, new treatments that prevent phagocytosis will be advantageous, especially for short‐term usage along with alternative options.Study Design and Methods: KB‐208, a small molecule drug, previously shown to be efficacious for the in vitro inhibition of phagocytosis was synthesized. A passive antibody mouse model of immune thrombocytopenia (ITP) was used. Three different mouse strains (BALB/c, C57BL/6, CD1) were used to determine the efficacy of KB‐208 compared with IVIG to ameliorate the ITP. Toxicity was investigated after 60‐day chronic administration of KB‐208 by a biochemistry panel, gross necroscopy and histopathology.Results: KB‐208 showed similar efficacy to ameliorate the thrombocytopenia compared with IVIG in all three mouse strains. This small molecule drug was effective at 1 mg/kg in ameliorating ITP, in comparison with IVIG at 1000–2500 mg/kg. KB‐208 did not affect other blood parameters or elevate serum biochemistry markers of toxicity nor were any abnormal histopathological findings found.Conclusion: KB‐208 is similar to IVIG for the amelioration of ITP in multiple mouse strains. Chronic administration of KB‐208 for 60 days did not demonstrate in vivo toxicity. These findings indicate that KB‐208 is efficacious, without significant in vivo toxicities in mice, and is a potential small molecule candidate for further evaluation to be used in the treatment of ITP and possibly all immune cytopenias where phagocytosis is responsible for the pathophysiology.
- Open Access
- 1 January 2024
- Published by Wiley in International Journal of Hepatology
- Vol. 2024 (1) , 5560676
Acyl‐CoA Thioesterase 1 Contributes to Transition of Steatosis to Metabolic‐Associated Steatohepatitis
Background. Metabolic dysfunction‐associated steatohepatitis (MASH) has become the leading cause of chronic liver disease, but there has been no approved pharmacotherapy to date. Methods. We used a network analysis approach to delineate protein‐protein interactions that contribute to the transition from steatosis to MASH, in order to identify and target this transition as a potential pharmacotherapeutic strategy. Acyl‐CoA thioesterase 1 (ACOT1) was identified as a critical node in the protein‐protein interaction (PPI) network of the transition from steatosis to MASH in patient samples. ACOT1 overexpression and silencing effects were tested in vivo on C57BL/6 mice exposed to high‐fat diet (HFD) and inoculated with an adenoviral system to modulate ACOT1 expression. Transcriptomic and untargeted lipidomic profiles were performed on the mouse livers. Results. ACOT1 expression was 3‐fold higher in MASH as compared to steatosis. In patient samples, ACOT1 was significantly correlated with the severity of MASH as reflected by the nonalcoholic fatty liver disease score. Experimental validation showed that downregulation of ACOT1 resulted in decreased lipid accumulation and prevention of MASH in vivo. Conversely, upregulation of ACOT1 via an adenoviral vector resulted in development of MASH, whereas control mice only developed steatosis. Lipidomic analysis revealed glycerophospholipids to be especially abundant in MASH accelerated by ACOT1 upregulation. Conclusion. These results suggest that ACOT1 contributes to the transition from steatosis to MASH through modulation of glycerophospholipid accumulation and its potential as a novel therapeutic target in MASH. This trial is registered with NCT02148471.
- 1 January 2024
- Published by Wiley in International Journal of Hepatology
- Vol. 2024 (1) , 5560676
Open AccessAcyl‐CoA Thioesterase 1 Contributes to Transition of Steatosis to Metabolic‐Associated Steatohepatitis
Background. Metabolic dysfunction‐associated steatohepatitis (MASH) has become the leading cause of chronic liver disease, but there has been no approved pharmacotherapy to date. Methods. We used a network analysis approach to delineate protein‐protein interactions that contribute to the transition from steatosis to MASH, in order to identify and target this transition as a potential pharmacotherapeutic strategy. Acyl‐CoA thioesterase 1 (ACOT1) was identified as a critical node in the protein‐protein interaction (PPI) network of the transition from steatosis to MASH in patient samples. ACOT1 overexpression and silencing effects were tested in vivo on C57BL/6 mice exposed to high‐fat diet (HFD) and inoculated with an adenoviral system to modulate ACOT1 expression. Transcriptomic and untargeted lipidomic profiles were performed on the mouse livers. Results. ACOT1 expression was 3‐fold higher in MASH as compared to steatosis. In patient samples, ACOT1 was significantly correlated with the severity of MASH as reflected by the nonalcoholic fatty liver disease score. Experimental validation showed that downregulation of ACOT1 resulted in decreased lipid accumulation and prevention of MASH in vivo. Conversely, upregulation of ACOT1 via an adenoviral vector resulted in development of MASH, whereas control mice only developed steatosis. Lipidomic analysis revealed glycerophospholipids to be especially abundant in MASH accelerated by ACOT1 upregulation. Conclusion. These results suggest that ACOT1 contributes to the transition from steatosis to MASH through modulation of glycerophospholipid accumulation and its potential as a novel therapeutic target in MASH. This trial is registered with NCT02148471.
- Open Access
- 19 July 2023
- Published by IntechOpen
Synthetic Strategies and Biological Activities of 1,5-Disubstituted Pyrazoles and 2,5-Disubstituted Thiazoles
Pyrazoles and thiazoles belong to 5-membered aromatic heterocycles called azoles. In addition to a nitrogen, pyrazoles contain an additional nitrogen in a 1,2 linkage and thiazoles contain a sulfur atom in a 1,3 linkage. These compounds are useful pharmacophores that offer a broad range of therapeutic applications. Pyrazoles can be synthesized by (i) the condensation of 1,3 dipolar compounds and alkenes/alkynes, (b) cyclocondensation of hydrazines and dicarbonyl reagents, and (c) multi-component reactions. Access to thiazoles is typically via (a) the condensation of α-haloketones with nucleophilic thioamides containing the N-C-S fragment, (b) a reaction between α-aminonitriles and various reactants containing an X-C-S fragment, and (c) a reaction of acylaminocarbonyls and phosphorus pentasulfide. This chapter will focus on the strategies and our perspectives on the synthesis of pyrazoles and thiazoles including derivatives at the 1,5 positions and 2, 4, 5 positions respectively, reported during 2015–2022. Additionally, their therapeutic and biological evaluations will be discussed.
- 19 July 2023
- Published by IntechOpen
Open AccessSynthetic Strategies and Biological Activities of 1,5-Disubstituted Pyrazoles and 2,5-Disubstituted Thiazoles
Pyrazoles and thiazoles belong to 5-membered aromatic heterocycles called azoles. In addition to a nitrogen, pyrazoles contain an additional nitrogen in a 1,2 linkage and thiazoles contain a sulfur atom in a 1,3 linkage. These compounds are useful pharmacophores that offer a broad range of therapeutic applications. Pyrazoles can be synthesized by (i) the condensation of 1,3 dipolar compounds and alkenes/alkynes, (b) cyclocondensation of hydrazines and dicarbonyl reagents, and (c) multi-component reactions. Access to thiazoles is typically via (a) the condensation of α-haloketones with nucleophilic thioamides containing the N-C-S fragment, (b) a reaction between α-aminonitriles and various reactants containing an X-C-S fragment, and (c) a reaction of acylaminocarbonyls and phosphorus pentasulfide. This chapter will focus on the strategies and our perspectives on the synthesis of pyrazoles and thiazoles including derivatives at the 1,5 positions and 2, 4, 5 positions respectively, reported during 2015–2022. Additionally, their therapeutic and biological evaluations will be discussed.
- Open Access
Small Molecule Drugs That Inhibit Phagocytosis
In our initial publication on the in vitro testing of more than 200 compounds, we demonstrated that small molecules can inhibit phagocytosis. We therefore theorized that a small molecule drug discovery-based approach to the treatment of immune cytopenias (ITP, AIHA, HTR, DHTR) is feasible. Those earlier studies showed that small molecules with anti-phagocytic groups, such as the pyrazole core, are good models for producing efficacious phagocytosis inhibitors with low toxicity. We recently screened a chemical library of 80 compounds containing pyrazole/isoxazole/pyrrole core structures and found four hit molecules for further follow-up, all having the pyrazole core structure. Subsequent evaluation via MTT viability, LDH release, and apoptosis, led to the selection of two lead compounds with negligible toxicity and high efficacy. In an in vitro assay for inhibition of phagocytosis, their IC50 values were 2–4 µM. The rational development of these discoveries from hit to lead molecule stage, viz. independent synthesis/scale up of hit molecules, and in vivo activities in mouse models of autoimmune disease, will result in the selection of a lead compound(s) for further pre-clinical evaluation.
Open AccessSmall Molecule Drugs That Inhibit Phagocytosis
In our initial publication on the in vitro testing of more than 200 compounds, we demonstrated that small molecules can inhibit phagocytosis. We therefore theorized that a small molecule drug discovery-based approach to the treatment of immune cytopenias (ITP, AIHA, HTR, DHTR) is feasible. Those earlier studies showed that small molecules with anti-phagocytic groups, such as the pyrazole core, are good models for producing efficacious phagocytosis inhibitors with low toxicity. We recently screened a chemical library of 80 compounds containing pyrazole/isoxazole/pyrrole core structures and found four hit molecules for further follow-up, all having the pyrazole core structure. Subsequent evaluation via MTT viability, LDH release, and apoptosis, led to the selection of two lead compounds with negligible toxicity and high efficacy. In an in vitro assay for inhibition of phagocytosis, their IC50 values were 2–4 µM. The rational development of these discoveries from hit to lead molecule stage, viz. independent synthesis/scale up of hit molecules, and in vivo activities in mouse models of autoimmune disease, will result in the selection of a lead compound(s) for further pre-clinical evaluation.
- Open Access
Bioactive Chemical Composition of Cannabis Extracts and Cannabinoid Receptors
Cannabis is widely used as a therapeutic drug, especially by patients suffering from psychiatric and neurodegenerative diseases. However, the complex interplay between phytocannabinoids and their targets in the human receptome remains largely a mystery, and there have been few investigations into the relationship between the chemical composition of medical cannabis and the corresponding biological activity. In this study, we investigated 59 cannabis samples used by patients for medical reasons. The samples were subjected to extraction (microwave and supercritical carbon dioxide) and chemical analyses, and the resulting extracts were assayed in vitro using the CB1 and CB2 receptors. Using a partial least squares regression analysis, the chemical compositions of the extracts were then correlated to their corresponding cannabinoid receptor activities, thus generating predictive models that describe the receptor potency as a function of major phytocannabinoid content. Using the current dataset, meaningful models for CB1 and CB2 receptor agonism were obtained, and these reveal the insignificant relationships between the major phytocannabinoid content and receptor affinity for CB1 but good correlations between the two at CB2 receptors. These results also explain the anomalies between the receptor activities of pure phytocannabinoids and cannabis extracts. Furthermore, the models for CB1 and CB2 agonism in cannabis extracts predict the cannabinoid receptor activities of individual phytocannabinoids with reasonable accuracy. Here for the first time, we disclose a method to predict the relationship between the chemical composition, including phytocannabinoids, of cannabis extracts and cannabinoid receptor responses.
Open AccessBioactive Chemical Composition of Cannabis Extracts and Cannabinoid Receptors
Cannabis is widely used as a therapeutic drug, especially by patients suffering from psychiatric and neurodegenerative diseases. However, the complex interplay between phytocannabinoids and their targets in the human receptome remains largely a mystery, and there have been few investigations into the relationship between the chemical composition of medical cannabis and the corresponding biological activity. In this study, we investigated 59 cannabis samples used by patients for medical reasons. The samples were subjected to extraction (microwave and supercritical carbon dioxide) and chemical analyses, and the resulting extracts were assayed in vitro using the CB1 and CB2 receptors. Using a partial least squares regression analysis, the chemical compositions of the extracts were then correlated to their corresponding cannabinoid receptor activities, thus generating predictive models that describe the receptor potency as a function of major phytocannabinoid content. Using the current dataset, meaningful models for CB1 and CB2 receptor agonism were obtained, and these reveal the insignificant relationships between the major phytocannabinoid content and receptor affinity for CB1 but good correlations between the two at CB2 receptors. These results also explain the anomalies between the receptor activities of pure phytocannabinoids and cannabis extracts. Furthermore, the models for CB1 and CB2 agonism in cannabis extracts predict the cannabinoid receptor activities of individual phytocannabinoids with reasonable accuracy. Here for the first time, we disclose a method to predict the relationship between the chemical composition, including phytocannabinoids, of cannabis extracts and cannabinoid receptor responses.
- 23 April 2020
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 374 (1) , 44-51
Topical Delivery of Muscarinic Receptor Antagonists Prevents and Reverses Peripheral Neuropathy in Female Diabetic Mice
Muscarinic antagonists promote sensory neurite outgrowth in vitro and prevent and/or reverse multiple indices of peripheral neuropathy in rodent models of diabetes, chemotherapy-induced peripheral neuropathy, and HIV protein-induced neuropathy when delivered systemically. We measured plasma concentrations of the M1 receptor–selective muscarinic antagonist pirenzepine when delivered by subcutaneous injection, oral gavage, or topical application to the skin and investigated efficacy of topically delivered pirenzepine against indices of peripheral neuropathy in diabetic mice. Topical application of 2% pirenzepine to the paw resulted in plasma concentrations 6 hours postdelivery that approximated those previously shown to promote neurite outgrowth in vitro. Topical delivery of pirenzepine to the paw of mice with streptozotocin-induced diabetes dose-dependently (0.1%–10.0%) prevented tactile allodynia, thermal hypoalgesia, and loss of epidermal nerve fibers in the treated paw and attenuated large fiber motor nerve conduction slowing in the ipsilateral limb. Efficacy against some indices of neuropathy was also noted in the contralateral limb, indicating systemic effects following local treatment. Topical pirenzepine also reversed established paw heat hypoalgesia, whereas withdrawal of treatment resulted in a gradual decline in efficacy over 2–4 weeks. Efficacy of topical pirenzepine was muted when treatment was reduced from 5 to 3 or 1 day/wk. Similar local effects were noted with the nonselective muscarinic receptor antagonist atropine when applied either to the paw or to the eye. Topical delivery of muscarinic antagonists may serve as a practical therapeutic approach to treating diabetic and other peripheral neuropathies. SIGNIFICANCE STATEMENT Muscarinic antagonist pirenzepine alleviates diabetic peripheral neuropathy when applied topically in mice.
- 23 April 2020
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 374 (1) , 44-51
Topical Delivery of Muscarinic Receptor Antagonists Prevents and Reverses Peripheral Neuropathy in Female Diabetic Mice
Muscarinic antagonists promote sensory neurite outgrowth in vitro and prevent and/or reverse multiple indices of peripheral neuropathy in rodent models of diabetes, chemotherapy-induced peripheral neuropathy, and HIV protein-induced neuropathy when delivered systemically. We measured plasma concentrations of the M1 receptor–selective muscarinic antagonist pirenzepine when delivered by subcutaneous injection, oral gavage, or topical application to the skin and investigated efficacy of topically delivered pirenzepine against indices of peripheral neuropathy in diabetic mice. Topical application of 2% pirenzepine to the paw resulted in plasma concentrations 6 hours postdelivery that approximated those previously shown to promote neurite outgrowth in vitro. Topical delivery of pirenzepine to the paw of mice with streptozotocin-induced diabetes dose-dependently (0.1%–10.0%) prevented tactile allodynia, thermal hypoalgesia, and loss of epidermal nerve fibers in the treated paw and attenuated large fiber motor nerve conduction slowing in the ipsilateral limb. Efficacy against some indices of neuropathy was also noted in the contralateral limb, indicating systemic effects following local treatment. Topical pirenzepine also reversed established paw heat hypoalgesia, whereas withdrawal of treatment resulted in a gradual decline in efficacy over 2–4 weeks. Efficacy of topical pirenzepine was muted when treatment was reduced from 5 to 3 or 1 day/wk. Similar local effects were noted with the nonselective muscarinic receptor antagonist atropine when applied either to the paw or to the eye. Topical delivery of muscarinic antagonists may serve as a practical therapeutic approach to treating diabetic and other peripheral neuropathies. SIGNIFICANCE STATEMENT Muscarinic antagonist pirenzepine alleviates diabetic peripheral neuropathy when applied topically in mice.
- 1 April 2020
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 132 (4) , 625-635
Cannabis Use Disorder and Perioperative Outcomes in Major Elective Surgeries
Background: Although cannabis is known to have cardiovascular and psychoactive effects, the implications of its use before surgery are currently unknown. The objective of the present study was to determine whether patients with an active cannabis use disorder have an elevated risk of postoperative complications. Methods: The authors conducted a retrospective population-based cohort study of patients undergoing elective surgery in the United States using the Nationwide Inpatient Sample from 2006 to 2015. A sample of 4,186,622 inpatients 18 to 65 yr of age presenting for 1 of 11 elective surgeries including total knee replacement, total hip replacement, coronary artery bypass graft, caesarian section, cholecystectomy, colectomy, hysterectomy, breast surgery, hernia repair, laminectomy, and other spine surgeries was selected. The principal exposure was an active cannabis use disorder, as defined by International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM) diagnostic codes for cannabis dependence and cannabis abuse. The primary outcome was a composite endpoint of in-hospital postoperative myocardial infarction, stroke, sepsis, deep vein thrombosis, pulmonary embolus, acute kidney injury requiring dialysis, respiratory failure, and in-hospital mortality. Secondary outcomes included hospital length of stay, total hospital costs, and the individual components of the composite endpoint. Results: The propensity-score matched-pairs cohort consisted of 27,206 patients. There was no statistically significant difference between patients with (400 of 13,603; 2.9%) and without (415 of 13,603; 3.1%) a reported active cannabis use disorder with regard to the composite perioperative outcome (unadjusted odds ratio = 1.29; 95% CI, 1.17 to 1.42; P < 0.001; Adjusted odds ratio = 0.97; 95% CI, 0.84 to 1.11; P = 0.63). However, the adjusted odds of postoperative myocardial infarction was 1.88 (95% CI, 1.31 to 2.69; P < 0.001) times higher for patients with a reported active cannabis use disorder (89 of 13,603; 0.7%) compared with those without (46 of 13,603; 0.3%) an active cannabis use disorder (unadjusted odds ratio = 2.88; 95% CI, 2.34 to 3.55; P < 0.001). Conclusions: An active cannabis use disorder is associated with an increased perioperative risk of myocardial infarction. Editor’s Perspective: What We Already Know about This Topic: What This Article Tells Us That Is New:
- 1 April 2020
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 132 (4) , 625-635
Cannabis Use Disorder and Perioperative Outcomes in Major Elective Surgeries
Background: Although cannabis is known to have cardiovascular and psychoactive effects, the implications of its use before surgery are currently unknown. The objective of the present study was to determine whether patients with an active cannabis use disorder have an elevated risk of postoperative complications. Methods: The authors conducted a retrospective population-based cohort study of patients undergoing elective surgery in the United States using the Nationwide Inpatient Sample from 2006 to 2015. A sample of 4,186,622 inpatients 18 to 65 yr of age presenting for 1 of 11 elective surgeries including total knee replacement, total hip replacement, coronary artery bypass graft, caesarian section, cholecystectomy, colectomy, hysterectomy, breast surgery, hernia repair, laminectomy, and other spine surgeries was selected. The principal exposure was an active cannabis use disorder, as defined by International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM) diagnostic codes for cannabis dependence and cannabis abuse. The primary outcome was a composite endpoint of in-hospital postoperative myocardial infarction, stroke, sepsis, deep vein thrombosis, pulmonary embolus, acute kidney injury requiring dialysis, respiratory failure, and in-hospital mortality. Secondary outcomes included hospital length of stay, total hospital costs, and the individual components of the composite endpoint. Results: The propensity-score matched-pairs cohort consisted of 27,206 patients. There was no statistically significant difference between patients with (400 of 13,603; 2.9%) and without (415 of 13,603; 3.1%) a reported active cannabis use disorder with regard to the composite perioperative outcome (unadjusted odds ratio = 1.29; 95% CI, 1.17 to 1.42; P < 0.001; Adjusted odds ratio = 0.97; 95% CI, 0.84 to 1.11; P = 0.63). However, the adjusted odds of postoperative myocardial infarction was 1.88 (95% CI, 1.31 to 2.69; P < 0.001) times higher for patients with a reported active cannabis use disorder (89 of 13,603; 0.7%) compared with those without (46 of 13,603; 0.3%) an active cannabis use disorder (unadjusted odds ratio = 2.88; 95% CI, 2.34 to 3.55; P < 0.001). Conclusions: An active cannabis use disorder is associated with an increased perioperative risk of myocardial infarction. Editor’s Perspective: What We Already Know about This Topic: What This Article Tells Us That Is New:
- Open Access
- 1 December 2019
- Published by SAGE Publications in Cannabis & Cannabinoid Research
- Vol. 4 (4) , 219-230
The Impact of Perioperative Cannabis Use: A Narrative Scoping Review
As countries progressively embrace the legalization of both medicinal and recreational cannabis, there remains a significant knowledge gap when it comes to the perioperative uses of cannabis, as well as the management of cannabis users. This review summarizes the information available on the subject based on existing published studies. Articles outlining the physiological changes occurring in the human body during acute and chronic use of cannabis (outside the context of anesthesia) are also taken into consideration as understanding these changes allows a more calculated approach to better anticipate patients' needs in the perioperative setting. Common questions facing the anesthesiologist at each phase of the perioperative period will be addressed and a systematic approach to the effect of cannabinoids on various organ systems will also be presented. Issues unique to cannabis use such as cannabis withdrawal syndrome and alterations in post-operative pain processing will also be discussed. To date, the number of studies available for guidance is small and study designs are markedly heterogenous, if not limited, making conclusions challenging. While the currently available information can assist in making decisions, further studies of larger scale are eagerly anticipated to help guide future patient care.
- 1 December 2019
- Published by SAGE Publications in Cannabis & Cannabinoid Research
- Vol. 4 (4) , 219-230
Open AccessThe Impact of Perioperative Cannabis Use: A Narrative Scoping Review
As countries progressively embrace the legalization of both medicinal and recreational cannabis, there remains a significant knowledge gap when it comes to the perioperative uses of cannabis, as well as the management of cannabis users. This review summarizes the information available on the subject based on existing published studies. Articles outlining the physiological changes occurring in the human body during acute and chronic use of cannabis (outside the context of anesthesia) are also taken into consideration as understanding these changes allows a more calculated approach to better anticipate patients' needs in the perioperative setting. Common questions facing the anesthesiologist at each phase of the perioperative period will be addressed and a systematic approach to the effect of cannabinoids on various organ systems will also be presented. Issues unique to cannabis use such as cannabis withdrawal syndrome and alterations in post-operative pain processing will also be discussed. To date, the number of studies available for guidance is small and study designs are markedly heterogenous, if not limited, making conclusions challenging. While the currently available information can assist in making decisions, further studies of larger scale are eagerly anticipated to help guide future patient care.